...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of rheumatology >Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials.
【24h】

Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials.

机译：Pennsaid膝关节骨关节炎的治疗：随机对照试验的系统评价和荟萃分析。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE: To systematically review published randomized controlled trials (RCT) evaluating a new topical diclofenac solution (Pennsaid) in patients with osteoarthritis (OA) of the knee. METHODS: RCT were identified by searching electronic data sources as well as by contact with the manufacturer of Pennsaid. Details of study demographics, methodology, quality, and outcomes were analyzed. A metaanalysis evaluating the efficacy and safety of Pennsaid in OA of the knee was performed. RESULTS: Four RCT were analyzed in this systematic review (3 published reports and one published abstract). Mean trial duration was 8.5 weeks. Generally, these RCT were of excellent quality. The mean Jadad quality score was 4.5 out of 5. Many indicators of high quality in a RCT were found in these RCT, including adequate descriptions of the methods used for randomization, blinding, and allocation concealment. In comparison to a vehicle control placebo (VCP), the standardized mean differences (SMD) for the WOMAC pain, stiffness, and physical function subscales, as well as for patient global assessment, were all statistically significant in favor of Pennsaid, with SMD ranging from 0.30 to 0.39. Pennsaid was as safe as VCP, with the only exception that it was more likely to result in minor skin dryness at the site of application (relative risk 1.7). In a 12 week equivalence trial that used the WOMAC subscales to compare treatment response, Pennsaid was as effective as oral diclofenac, but was much better tolerated. CONCLUSION: Pennsaid is an effective topical NSAID in patients with OA of the knee. Apart from minor localized skin reactions, Pennsaid was as safe as VCP. It is not known whether the favorable results of Pennsaid can be extrapolated to other topical NSAID preparations. Pennsaid deserves further consideration when the existing treatment guidelines for OA of the knee are updated.
机译：目的：系统评价已发表的随机对照试验（RCT），该试验评估膝关节骨关节炎（OA）患者的新型局部双氯芬酸溶液（Pennsaid）。方法：通过搜索电子数据源以及与Pennsaid的制造商联系来确定RCT。分析了研究人口统计学，方法，质量和结果的详细信息。进行荟萃分析，评估Pennsais在膝骨OA中的疗效和安全性。结果：本系统评价分析了4篇RCT（3篇发表的报告和1篇发表的摘要）。平均试验时间为8.5周。通常，这些RCT具有出色的质量。平均Jadad质量得分为4.5（满分5分）。在这些RCT中发现了许多RCT中的高质量指标，包括对随机化，盲法和隐藏分配方法的充分描述。与媒介物对照安慰剂（VCP）相比，WOMAC疼痛，僵硬和身体功能次级量表以及患者总体评估的标准化平均差异（SMD）在统计学上均显着有利于Pennsaid，SMD范围从0.30到0.39。 Pennsaid与VCP一样安全，唯一的例外是在应用部位更可能导致皮肤轻微干燥（相对危险度1.7）。在一项为期12周的等效试验中，使用WOMAC量表比较治疗反应，Pennsaid与口服双氯芬酸一样有效，但耐受性要好得多。结论：Pennsaid是一种有效的局部NSAID治疗膝关节炎的患者。除了轻微的局部皮肤反应外，Pennsaid与VCP一样安全。尚不可以将Pennsaid的良好结果推广到其他局部用的NSAID制剂中。当更新现有的膝盖骨关节炎的治疗指南时，Pennsaid应该进一步考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号